Actavis Hong Kong
Financially Compelling TransactionActavis continues to expect the transaction to be more than 30 percent accretive to Actavis non-GAAP earnings per share in 2014, including anticipated after-tax
For more information visit our Corporate Website, Actavis.com
Available in English only.
• $8.0 billion anticipated pro forma combined revenue in 2012
• Significantly increases scale of Watson’s ex-U.S. generic business
• Accelerates revenue and earnings growth